← 治験一覧に戻る
日本人アトピー性皮膚炎患者におけるデュピルマブ
基本情報
- NCT ID
- NCT04678882
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 62
- 治験依頼者名
- Sanofi
概要
Primary Objective: To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) Secondary Objective: To evaluate the efficacy of dupilumab administered concomitantly with TCS. To assess the safety of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in participants. To assess immunogenicity as determined by the incidence, titer, and clinical impact of treatment-emergent anti-drug antibodies (ADA) to dupilumab over time in pediatric patients with atopic dermatitis (AD) (aged ≥6 months to \<18 years old) To assess the concentration of dupilumab in serum following administration concomitantly with TCS.
対象疾患
Atopic Dermatitis
介入
Placebo(DRUG)
Dupilumab SAR231893(DRUG)